[EN] BENZYLBENZENE DERIVATIVES AND METHODS OF USE<br/>[FR] DÉRIVÉS DE BENZYLBENZÈNE ET PROCÉDÉS D'UTILISATION
申请人:THERACOS INC
公开号:WO2009026537A1
公开(公告)日:2009-02-26
Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
The present invention provides novel benzopyran compounds, pharmaceutically acceptable salts thereof and stereoisomers thereof where the benzopyran compounds of the invention are compounds according to Formula I:
The present invention further provides pharmaceutical compositions which possess anti-estrogenic activity and comprise at least one benzopyran compound of the invention and a method of treating breast cancer by administration of an effective amount of a benzopyran compound provided by the present invention.
Synthesis and physical properties of new fluoroether sulfones
作者:Zheng Yue、Xinyi Mei、Hamza Dunya、Qiang Ma、Christopher McGarry、Braja K. Mandal
DOI:10.1016/j.jfluchem.2018.10.014
日期:2018.12
Eight new strategically designed fluoroether sulfone solvents have been synthesized through different synthetic pathways for potential applications in lithium-sulfur battery electrolytes. The structures of these compounds have been confirmed by 1H-NMR, 13C-NMR and elemental analysis. Several 1,2-dimethoxyethane (DME)-based electrolyte formulations have been prepared with these solvents to derive an
已经通过不同的合成途径合成了八种新的经过战略设计的氟醚砜溶剂,可用于锂硫电池电解质中。这些化合物的结构已通过1 H-NMR,13 C-NMR和元素分析得到证实。已经使用这些溶剂制备了几种基于1,2-二甲氧基乙烷(DME)的电解质配方,以得到具有良好离子电导率(在25℃下> 5 mS cm -1)的电解质。这些新添加剂的粘度也已经确定,因为它与离子电导率直接相关。这些包含三氟甲基的溶剂中的三种显示出可接受的离子电导率。
BENZYLBENZENE DERIVATIVES AND METHODS OF USE
申请人:Theracos, Inc.
公开号:US20140031300A1
公开(公告)日:2014-01-30
Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.